Published in AIDS Weekly, August 5th, 1996
Researchers from the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), Chiron Corporation and Upjohn reported in the July 1996 issue of Antimicrobial Agents and Chemotherapy (Antimicrob Agents Chemother 1996;40:1657-1664).
Dr. R.T. Davey, Jr., of the NIAID and coworkers studied the safety, toxicity, pharmacokinetics and antiretroviral activity of DLV alone and in combination with zidovudine or didanosine or both. Eighty-five HIV positive patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.